Survivin is an anti-apoptotic gene that is overexpressed in most human tumors. RNA interference using short interfering RNA (siRNA) can be used to specifically inhibit survivin expression. Tumor cells were treated with a newly designed survivin siRNA, which was modified with 2′-OMe. Cellular survivin mRNA and protein levels were determined by real-time qRT-PCR and Western blot, respectively. Cell cycle and apoptosis were determined by flow cytometry. Cell proliferation was measured by MTT assay. Our data showed that the novel survivin-targeted siRNA could efficiently knockdown the expression of survivin and inhibit cell proliferation. Survivin mRNA was reduced by 95% after 48h treatment with 20nM siRNA. In addition, the siRNA could markedly arrest the cell cycle at the G2/M checkpoint and induce cellular apoptosis in a dose-dependent manner. The percentage of apoptotic cells reached 50% when treated with 40nM siRNA. In conclusion, we have identified a novel chemically modified siRNA against survivin that is highly efficient and delineated its mechanism of action, thus demonstrating a potential therapeutic role for this molecule in cancer. Further evaluation of this siRNA for therapeutic activity is warranted.
Introduction
Survivin is a member of the inhibitor of apoptosis (IAP) protein family [1, 2] . It inhibits apoptosis and regulates cell division [3] [4] [5] [6] . Sustained overexpression of survivin has been shown to be cancer specific [7] [8] [9] . In addition, elevated expression of survivin plays a significant role in the inhibition of apoptosis [10] [11] [12] [13] .These factors suggest that survivin is a potential therapeutic target [14] .
Growth inhibition and apoptosis induction are important mechanisms of cancer therapy [15] . RNA interference (RNAi) by small interfering RNA (siR-NA) can be used to reduce target gene expression in a sequence specific manner by degradation of the corresponding mRNA [16] [17] [18] [19] . After uptake by cells, siRNA is loaded into a RNA-induced silencing complex (RISC) [20, 21] . The passenger strand is then degraded and the remaining strand (guide strand) binds to a complementary RNA molecule, which is then degraded [22] . Gene silencing induced by siRNA is highly efficient and specific to the target gene and therefore has potential application in cancer treatment [23, 24] .
In recent years, several siRNA sequences targeting survivin have been reported [25] . However, they generally show only moderate activity [26] . Unmodified siRNA have issues such as poor stability, off-target effect and immune stimulation [27] . Indeed, modifications of the siRNA backbone by chemical groups, such as 2′-O-methyl (OMe) and 2′-fluoro (F), alone or in combination [28, 29] , can improve serum stability and reduce off-target effects [30] . However, siRNA modification can adversely affect its gene-silencing activity, thus presenting a critical challenge for siRNA drug development [31] .
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In order to achieve maximum therapeutic effect, it is essential to identify the most active form of drugs. Therefore, several 2′-OMe chemical groups were introduced into a novel survivin siRNA (siRNA-1) and the improvement in potency was evaluated in vitro in the present study.
Results and Discussion

Down-regulation of survivin in human tumor cell lines
Silencing of survivin expression was examined in a number of cell lines representing different types of tumors (MCF-7, A549, HeLa, and HepG2). Following transfection of cells with 10nM siRNA-1, the protein of survivin was determined by Western blot. HeLa and A549 cells had higher expression of survivin compared with the HepG2 and MCF-7 cells. In these cell lines, the siRNA targeting survivin successfully down-regulated the expression levels of survivin protein after 48h treatment with siRNA-1 ( Figure 1A ). The mRNA levels of survivin were determined by real-time qRT-PCR at 48h after transfection with different concentrations of siRNA-1 in HeLa cells. As shown in Figure 1B , survivin transcription was reduced by more than 70% at the transcriptional level. At 20nM siRNA, survivin mRNA was reduced by 95%. Analysis by immunofluorescence revealed survivin localization in the nucleus. In cells treated with increasing concentrations of siRNA-1, the fluorescence intensity was gradually diminished ( Figure  1C ). The cells treated with 20nM siRNA-1 had the weakest fluorescence intensity under a fluorescence microscope. These data suggested concentration-dependent down-regulation of survivin by siR-NA-1. In addition, as shown in Figure 1A , the differential expression of survivin in the cells treated by siRNA was cell-line dependent.
Effectiveness of siRNA in MCF-7 cells
In order to validate the efficiency of siRNA-1 on MCF-7 cells, dosages and durations of treatment were varied. Following transfection by siRNA-1, survivin mRNA and protein expression levels in MCF-7 cells were determined by real-time RT-PCR and Western blot, respectively. As shown in Figure 2A , B, the positive control (siRNA-2) and novel sequence siRNA (siRNA-1) both down-regulated survivin mRNA/protein expression relative to untreated and negative control (siRNA-3) treated cells. With the increasing concentration of siRNA, mRNA and protein levels of survivin were both reduced to a greater extent. At the same dosage, the potency of new siRNA-1 was nearly 1.8 times as high as the positive control, siRNA-2. In addition, protein levels of survivin were analyzed by Western blot at 24, 48 and 72h after transfection ( Figure 2C ). At 24h after transfection, survivin protein was already reduced. Survivin expression inhibition reached 80% after 72h. In contrast, the inhibitory effect of positive control siRNA-2 was not significant and the siRNA modified by 2′-OMe was more efficient than ordinary siRNA. 
siRNA induced G2/M Cell Cycle Arrest
In addition to the suppression of survivin, we evaluated the effect of siRNA on proliferation and progression of cell cycle in HeLa cells. Treatment of cells by siRNA-1 at 48h induced G2/M cell cycle arrest. In addition, the G0/G1 phase ratio decreased significantly ( Figure 3A , B). Cell cycle arrest reached the maximum at 48h ( Figure 3C , D). At 72 h after transfection, the G2 phase was still blocked. In the meantime, the percentage of cells in the S phase was increased. Based on these data, cell cycle arrest was induced by siRNA-1, mainly at the G2/M phases.
Inhibitory effect on cell proliferation by siRNA
Treatment of HeLa cells with siRNA-1 over 72h caused remarkable reductions in cell proliferation compared to non-treated cells ( Figure. 4A ). At 72h after transfection, cell proliferation inhibition rate reached to nearly 50%. Furthermore, the effect of siRNA-1 on growth of HeLa cells was investigated ( Figure. 4B ). The number of surviving cells treated with 40nM siRNA-1 on the fourth day was 50% relative to the control group.
siRNA induces cell apoptosis and alters apoptosis-related signaling molecules in HeLa cells
The effect on the cell cycle and proliferation from siRNA-1 was obvious. Cell apoptosis was also studied. Treatment of HeLa cells with different concentrations of siRNA-1 induced different degrees of apoptosis detected by flow cytometry. As shown in Figure  5A , the percentage of apoptotic cells increased with the concentration of siRNA-1. When the concentration of siRNA reached 40nM, the percentage of apoptotic cells was reached 50%. To characterize the molecular mechanism by which survivin alters apoptosis in HeLa cells, we examined the expression of apoptosis-associated proteins in response to survivin. The expression levels of p-Akt, Bax, and Bad were examined using Western blot at 48 h after transfection (Figure. 5B). The protein levels were quantified by densitometry ( Figure. 5C ). Apoptosis-inducing proteins Bax and Bad were increased in response to the down-regulation of survivin. This showed that siR-NA-1 promoted cell apoptosis via Bad and Bax. At the same time, Akt signaling pathway was involved, and the level of p-Akt was similarly down-regulated with a decrease of survivin. In a subsequent experiment, we examined whether siRNA could inhibit the decrease of mitochondrial membrane potential (∆ψm) induced by siRNA (Fig.6A) . Under the control conditions, JC-1 emitted high intensity of red fluorescence, and with the increasing concentration of siRNA-1, red fluorescence intensity became weaker compared with control. The data demonstrated that siRNA promoted the dissipation of ∆ψm, which confirmed that cell apoptosis was induced by the Akt signal pathway. In summary, siRNA-1 can affect cell cycle progression, cause G2/M phase arrest and induce tumor cell apoptosis, particularly through the AKT pathway.
Experimental Section
siRNA Design
siRNAs were purchased from Guangzhou RiboBio Co. (Guangzhou, China). The sequences used are as follows (Table 1) . siRNA purification was conducted by reverse-phase high performance liquid chromatography (HPLC). The second siRNA (siR-NA-2), adopted from a previous study, was used as the positive control targeting survivin [26] . The third siRNA (siRNA-3) was used as a negative control. 
Cell lines and cell culture
Cell lines were purchased from the American Type Culture Collection (ATCC; Rockville, MD). Cells were grown in DMEM or RPMI-1640 medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics/antimycotics (Sigma-Aldrich, St. Louis, MO) at 37˚C in a humidified atmosphere containing 5% CO2.
Cell Transfection
Cells (1.4~1.6×10 5 cells/well) were seeded in 6-well plates and incubated at 37˚Cuntilthey reached60-70%confluency. Before transfection, culture medium was removed and replaced with fresh serum-free Opti-MEMI (Gibco) medium. Tumor cells were transfected with siRNA-1 or controls using RNAiMAX (Invitrogen, Grand Island, NY). The cul-ture supernatant was replaced after 4h and fresh medium containing 10% FBS was added. The cells were harvested and evaluated after 48h.
Real-time RT-PCR for determination of survivin mRNA
Survivin gene expression was determined by real-time RT-PCR. Total RNA was extracted from the transfected cells using TRIZOL reagent (TaKaRa, Dalian, China). Complementary deoxyribonucleic acids (cDNAs) were synthesized by reverse transcription from 1μg of total RNA. Forward and reverse primers used were as follows: 5'-CAGTGTTTCTTCTGC TTCAAGG-3' and 5'-CTTATTGTTGGTTTCCTTT GCAT-3' (Sangon Biotech, China). SYBR Green PCR kit (TaKaRa, Dalian, China) was used for the PCR reaction and each sample was analyzed in triplicate. The relative expression of each mRNA was detected and normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as described [32] .
Western blot analysis for expression of survivin protein
Western blot analysis was performed following standard methods [33] . After a period of incubation, cells were washed twice with PBS. Total protein was extracted on ice by RIPA (Sigma-Aldrich, St. Louis, MO). Protein concentration was measured using a bicinchoninic acid (BCA) protein assay kit (Bio-rad, Hercules, CA). Electrophoretic analysis of 30μl protein from each sample was performed by SDS-PAGE. The proteins are transferred to a PVDF membrane after the separation. The detection of target protein was carried out using a secondary antibody (sheep anti-rabbit antibody, 1:10000 dilutions, Pierce, Rockford, IL, USA) following the primary antibody (rabbit anti-human survivin antibody, 1:1000 dilutions, Cell Signaling Technology, Inc.). Binding was detected using an enhanced chemiluminescence (ECL) kit (GE Healthcare, United Kingdom). The results were analyzed by gel imaging and analysis system (Upland, CA, USA).
Visualization of survivin expression by fluorescence microscopy
The expression of survivin in cancer cells was detected using immunofluorescence [34] . Coverslips were placed into a 12 well plate and cells were seeded (1×10 4 ) into the coverslips/well. The cells were incubated overnight at 37˚C. Tumor cells were transfected with different concentrations of siRNA-1. After 48h, medium was removed from wells. The cells were washed with warm PBS and fixed in 4% paraformaldehyde/PBS for 15min. Cells were permeabilized by TritonX-100 and then treated with primary survivin antibody and FITC-conjugated donkey anti-goat antibody. Then, mounting solution was added. The cells were visualized on a fluorescence microscope in the dark.
Flow Cytometry analysis of cell cycle and apoptosis
Cell cycle and apoptosis were determined by flow cytometry [35] . Cells (2×10 5 cells/well) were plated onto 6-well plates overnight and then replaced with serum free medium for cell cycle synchronization. Then the cells were treated with 10, 20, 40nM siRNA complex.
The cells were harvested and fixed in 75% methanol at 4℃ overnight. The cells were washed twice with cold PBS and stained with PI (0.5mg/ml RNase, and 0.1mg/ml PI in PBS) for 30 min at room temperature. The stained cells were characterized by a flow cytometer flow cytometer (Beckman Coulter Corp., Tokyo, Japan), and DNA content was analyzed by FlowJo software.
After 48h, the cells were harvested and washed twice with PBS. The cells were stained using Annexin V-FITC/PI kit (KeyGEN Biotech, China), following manufacturer's protocol.
After incubation for 20 min at room temperature in the dark, cell apoptosis was immediately detected on a flow cytometer as described [36, 37] .
MTT Assay
Cell viability was measured by MTT assay [38] . Cells (1×10 4 cells/well) were grown in 96-well plates and incubated overnight. Various concentrations of siRNA (0-50nM) and RNAiMAX complexes were added to the cells after the replacement of culture medium with serum free medium. The medium was removed after 4 h and the cells were cultured in fresh medium for a period of time. MTT assay was performed to evaluate cell viability. Briefly, 20μl MTT stock solution (5mg/ml in PBS) was added and incubated for 4 h at 37˚C. The medium was then removed. After that, 150μl /well DMSO was added to dissolve formazan crystals that formed and the absorbance was measured at 540 nm using an automatic microplate reader (Biotek, VT, USA) [39] .
Cell proliferation
Cells (1×10 4 cells/well) were grown in 24-well plates and incubated overnight. Different concentrations of siRNA complexes were added and after 4 h incubation, the cells were cultured in fresh medium. Cells from three wells were counted with trypan blue staining method in each group every day. The survival rate of the cells was observed for a total of seven days.
Mitochondrial membrane potential analysis
JC-1 (5, 5´, 6, 6´-tetrachloro-1, 1´, 3, 3´-tetraethylbenzimidazol carbocyanine iodide, Sigma-Aldrich), a fluorescent probe, was used to measure alterations in ∆ψm. Healthy cells with a high ∆ψm exhibit red fluorescence. Meanwhile, apoptotic or unhealthy cells with a low ∆ψm exhibit green fluorescence (19) . HeLa cells were seeded onto dishes at a density of 1x10 5 cells/well. Subsequent to pretreatment with different concentrations of siRNA, cells were incubated with JC-1 at a final concentration of 2 µM at 37˚C for 15 min in the dark. Cells were washed with PBS and changes in mitochondrial fluorescence were analyzed on a fluorescent microscope.
Statistical Analysis
The data were analyzed using SPSS 16.0 software (IBM, Armonk, New York). The difference between two independent samples was analyzed by Student's t test. A statistically significant difference was considered to be present at p<0.05.
Conclusions
Because survivin is an essential component of most types of cancers [40] [41] [42] , it can serve as a biomarker for a number of malignancies [43] [44] [45] . Although targeting survivin by siRNA has shown some promise in cancer, the potency of siRNA needs further improvement. In order to achieve maximum therapeutic effect, however, it is essential to identify the most active form of siRNA drugs. In this respect, rational design of the siRNA itself must precede the design of the delivery vehicle.
We have shown that a novel siRNA sequence we designed (siRNA-1), which was modified by several 2′-OMe chemical groups in both strands, is much better than the positive control sequence reported previously. In addition, the suppression of siRNA was cell-line dependent. Meanwhile, siRNA-1 exerted a significant effect on cell proliferation and cell cycle by enhancing the G2/M phase arrest. The contribution of siRNA to cell proliferation, inhibition, and cell apoptosis were also regulated and controlled by signaling pathways. For instance, Bad and Bax expression increased in the cancer cells treated with siRNA, along with induction of apoptosis. Moreover, the Akt-mediated signal pathway may be involved in apoptosis induction. In response to apoptotic stimuli, survivin is trafficked from the mitochondria to the cytosol where it can inhibit apoptosis. Similarly the decreasing ∆ψm is one of the important hallmarks of cellular apoptosis [46, 47] . The results of this study suggest that the novel siRNA sequence has high potency and warrants further evaluation as a therapeutic agent. Clinical translation of siRNA requires both optimization of the siRNA design and development of an efficient delivery vehicle. Our future work will focus on assessing the in vivo activities of the novel survivin siRNA.
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